• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Cabaletta Bio Inc.

    6/20/25 5:22:59 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CABA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Cabaletta Bio, Inc.

    (Name of Issuer)


    Common stock, par value $0.00001 per share (the "Shares")

    (Title of Class of Securities)


    12674W109

    (CUSIP Number)


    06/12/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    12674W109


    1Names of Reporting Persons

    Citadel Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,687,280.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,687,280.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,687,280.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    IA, HC, OO

    Comment for Type of Reporting Person:  The percentages reported in this Schedule 13G are based upon 92,943,101 Shares outstanding comprised of (i) 89,943,101 Shares outstanding as of immediately following the issuer's public offering (according to the issuer's Prospectus Supplement as filed with the Securities and Exchange Commission on June 12, 2025), and (ii) 3,000,000 Shares issuable upon conversion of certain warrants held by affiliates of the reporting persons. Except as described in the preceding sentence, all Shares for the holdings of the reporting persons reported in this Schedule 13G are as of the opening of the market on June 20, 2025.


    SCHEDULE 13G

    CUSIP No.
    12674W109


    1Names of Reporting Persons

    Citadel Advisors Holdings LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,687,280.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,687,280.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,687,280.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP No.
    12674W109


    1Names of Reporting Persons

    Citadel GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,687,280.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,687,280.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,687,280.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    12674W109


    1Names of Reporting Persons

    Citadel Securities LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    131,280.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    131,280.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    131,280.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.1 %
    12Type of Reporting Person (See Instructions)

    BD, OO


    SCHEDULE 13G

    CUSIP No.
    12674W109


    1Names of Reporting Persons

    Citadel Securities Group LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    131,280.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    131,280.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    131,280.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.1 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP No.
    12674W109


    1Names of Reporting Persons

    Citadel Securities GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    131,280.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    131,280.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    131,280.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.1 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    12674W109


    1Names of Reporting Persons

    Kenneth Griffin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,818,560.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,818,560.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,818,560.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Cabaletta Bio, Inc.
    (b)Address of issuer's principal executive offices:

    2929 Arch Street Suite 600 Philadelphia, PA, 19104
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being jointly filed by Citadel Advisors LLC ("Citadel Advisors"), Citadel Advisors Holdings LP ("CAH"), Citadel GP LLC ("CGP"), Citadel Securities LLC ("Citadel Securities"), Citadel Securities Group LP ("CALC4"), Citadel Securities GP LLC ("CSGP") and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the "Reporting Persons") with respect to the Shares of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company ("CM"), and Citadel Securities. Such owned Shares may include other instruments exercisable for or convertible into Shares. Citadel Advisors is the portfolio manager for CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP. The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
    (b)Address or principal business office or, if none, residence:

    The address of each of CSGP, Citadel Securities and CALC4 is 830 Brickell Plaza, Miami, Florida 33131. The address of the other Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131.
    (c)Citizenship:

    Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.
    (d)Title of class of securities:

    Common stock, par value $0.00001 per share (the "Shares")
    (e)CUSIP No.:

    12674W109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 4,687,280 Shares. 2. Citadel Securities LLC may be deemed to beneficially own 131,280 Shares. 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 131,280 Shares. 4. Mr. Griffin may be deemed to beneficially own 4,818,560 Shares.
    (b)Percent of class:

    1. The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 5.0% of the Shares outstanding. 2. The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.1% of the Shares outstanding. 3. The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.1% of the Shares outstanding. 4. The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 5.2% of the Shares outstanding.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0 2. Citadel Securities LLC: 0 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0 4. Mr. Griffin: 0

     (ii) Shared power to vote or to direct the vote:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 4,687,280 2. Citadel Securities LLC: 131,280 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 131,280 4. Mr. Griffin: 4,818,560

     (iii) Sole power to dispose or to direct the disposition of:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0 2. Citadel Securities LLC: 0 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0 4. Mr. Griffin: 0

     (iv) Shared power to dispose or to direct the disposition of:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 4,687,280 2. Citadel Securities LLC: 131,280 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 131,280 4. Mr. Griffin: 4,818,560

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Citadel Advisors LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:06/20/2025
     
    Citadel Advisors Holdings LP
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:06/20/2025
     
    Citadel GP LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:06/20/2025
     
    Citadel Securities LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:06/20/2025
     
    Citadel Securities Group LP
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:06/20/2025
     
    Citadel Securities GP LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:06/20/2025
     
    Kenneth Griffin
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, attorney-in-fact*
    Date:06/20/2025

    Comments accompanying signature:  * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.
    Exhibit Information

    Exhibit 99.1 - Joint Filing Agreement

    Get the next $CABA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CABA

    DatePrice TargetRatingAnalyst
    12/20/2024$15.00 → $6.00Outperform → In-line
    Evercore ISI
    12/19/2024$12.00 → $6.00Overweight → Equal Weight
    Wells Fargo
    10/10/2024$10.00Buy
    UBS
    2/5/2024$36.00Buy
    Jefferies
    11/29/2023$38.00Outperform
    William Blair
    10/24/2023$40.00Overweight
    Cantor Fitzgerald
    10/19/2023$31.00Buy
    Stifel
    9/5/2023$22.00Buy
    Citigroup
    More analyst ratings

    $CABA
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Cabaletta Bio Inc.

      SCHEDULE 13G - Cabaletta Bio, Inc. (0001759138) (Subject)

      6/20/25 5:22:59 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Cabaletta Bio Inc.

      8-K - Cabaletta Bio, Inc. (0001759138) (Filer)

      6/12/25 6:05:29 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Cabaletta Bio Inc.

      424B5 - Cabaletta Bio, Inc. (0001759138) (Filer)

      6/12/25 6:03:33 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Simon Mark

      4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

      6/9/25 8:28:01 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Brun Scott C.

      4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

      6/9/25 8:22:15 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Bollard Catherine

      4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

      6/9/25 8:20:03 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cabaletta Bio downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Cabaletta Bio from Outperform to In-line and set a new price target of $6.00 from $15.00 previously

      12/20/24 7:29:05 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Cabaletta Bio from Overweight to Equal Weight and set a new price target of $6.00 from $12.00 previously

      12/19/24 7:31:17 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • UBS initiated coverage on Cabaletta Bio with a new price target

      UBS initiated coverage of Cabaletta Bio with a rating of Buy and set a new price target of $10.00

      10/10/24 7:27:43 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cabaletta Bio Announces Pricing of Public Offering of Securities

      PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten public offering consisting of (i) 39,200,000 shares of its common stock and accompanying warrants to purchase an aggregate of 39,200,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to 10,800,000 shares of its common stock and accom

      6/11/25 9:54:40 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio Announces Proposed Public Offering of Securities

      PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock, to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in li

      6/11/25 6:15:28 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

      – 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all responding patients – – All SLE patients without nephropathy achieved definition of remission in SLE (DORIS) as of the latest follow-up, and all 7 SLE and LN patients experienced SLEDAI-2K reductions, while off all immunomodulators and steroids – – Both scleroderma patients demonstrated clinically compelling mRSS improvement after discontinuation of all immunomodulators and steroids – – In 18 patients with follow-up of 4 weeks or more, 94% had either no CRS or Grade 1

      6/11/25 6:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    Leadership Updates

    Live Leadership Updates

    See more
    • Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

      – Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition by Gilead Sciences – PHILADELPHIA, July 24, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello has over 35 years of experience in the life sciences industry, including specific expertise in CD19-CAR T therapy, where she most recently served as the Chief Commercial Officer of Kite Pharma, Inc. between 20

      7/24/23 8:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors

      Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper's Board of Directors. Dr. Bru

      6/20/23 8:00:00 AM ET
      $CABA
      $FBRX
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel

      PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Michael Gerard has been appointed general counsel. "We are very pleased to welcome Mike to the executive team. His experience with a wide range of strategic legal and corporate matters within the life sciences industry will complement the management team as we advance clinical development for DSG3-CAART in our DesCAARTes™ trial, and further develop follow-on candidates from our deep pipeline of precision therapies for pati

      9/7/21 8:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    Financials

    Live finance-specific insights

    See more
    • Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

      – CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – Compelling clinical responses observed in lupus and myositis patients with up to six months of follow-up; first SSc patient demonstrated an emerging, drug-free clinical response – – All eight patients with active, refractory autoimmune disease discontinued all immunosuppressants prior to CABA-201 infusion and through the follow-up period – – Consistent and complete B cell depletion observed in all patients within the first month after CABA-201 infusion; evidence of transitional naïve B cell repopula

      11/18/24 7:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

      – Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR Convergence 2024 – – 16 patients enrolled with 10 patients dosed as of November 12 across the RESET™ clinical development program; 40 U.S. clinical sites actively recruiting patients – – Data permitting, anticipate meeting with the FDA in 2025 regarding potential registrational program designs for CABA-201 – – Clinical development expanding efficiently into Europe with EMA CTA authorization for CABA-201 received in lupus; Gerwin Winter appointed as Senior VP and Head of International – – Cash, cash

      11/14/24 7:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

      – No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both patients by day 15 post-infusion – – Improvements in both patients' specific disease measures, consistent with academic experience of a similar 4-1BB CD19-CAR T, suggest emerging clinical benefit with CABA-201 while discontinuing all disease-specific therapies other than a planned steroid taper in one patient – – Immature, naïve B cell repopulation in first IMNM patient observed at week 8 consistent with a potential immu

      6/14/24 2:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

      SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

      12/6/24 4:05:57 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

      SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

      12/5/24 4:50:19 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

      SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

      12/5/24 3:36:55 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care